Press Releases

UsAgainstAlzheimer’s has issued the following statements, remembering and honoring music icon Glen Campbell, who died today following an arduous battle with Alzheimer’s disease. Campbell, who was 81 years old, was diagnosed with the disease in 2011, and he, his wife Kim Campbell and their family have fought fearlessly to make progress against this disease and support caregivers.   

UsAgainstAlzheimer’s applauds the National Institutes of Health’s (NIH) recommendation to Congress and the Administration that FY 19 research funding for Alzheimer’s, a disease that affects 5.5 million Americans and their caregivers, must increase by nearly $600 million from the current FY 17 level of $1.4 billion.

“We must not be fooled by a procedural vote. UsAgainstAlzheimer’s is concerned by any momentum in Congress to advance policies that may weaken or eliminate health care for people with Alzheimer’s and related dementias,” Vradenburg said. “We urge Congress to ensure that the impact of health reform on millions of elderly, sick and low-income Americans is a central consideration in any forthcoming deliberation of a replacement bill.” 

Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer’s pipeline analysis presented today at the Alzheimer’s Association International Conference (AAIC) by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s network. 

Following the release of the revised Better Care Reconciliation Act, UsAgainstAlzheimer’s maintains its opposition to any legislation that would reduce access to affordable care for millions of low-income, elderly and sick Americans, and may weaken protections for many Americans with or at risk of Alzheimer’s, a disease that has no cure and one that often goes misdiagnosed.  


^ Back to Top